Shares of Novavax (NASDAQ: NVAX), a clinical-stage vaccine company focused on developing nanoparticle and recombinant vaccines to treat and prevent a variety of diseases, tanked and fell as much as 11% during Tuesday’s trading session, after the company reported its fourth-quarter earnings results and updating investors on its pipeline development.